Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-10-06

Clinical Trial Update: ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial [Phase 2]

View source ↗

Summary

A Phase 2 trial of ZACtima/FASlodex for postmenopausal advanced breast cancer was terminated, with results posted on 2014-10-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Faslodex (fulvestrant)
  • Zactima (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-10-06